Polysaccharide-based carriers can not only enhance the solubility of poorly water-soluble drugs but can also generate new types of first in class of new drugs and controlled-release formulations, long-acting formulations, or extended-releasing formulations for poorly water-soluble drugs.  In addition, our technology platform GlycoTDSTM  has "high tunability" to a variety of drug payloads and the capability to combine active tumor targeting using tumor receptor targeting ligands or macropinocytosis pathway with passive tumor targeting using supra-molecular polymers EPR effects. This endows polysaccharide-based drug conjugates with dual targeting effects that can effectively attack a wide range of tumor targets. The GlycoTDSTM  platform may address currently challenges and bottlenecks using monoclonal antibodies (mAbs) and small molecules.

Compatible spaces and application potentials of  our platform GlycoTDSTM 

Drug loading compatible space of polysaccharide-based drug delivery system platform

1) Small molecular drugs; 2)Peptide drugs; 3) Small molecular nucleic acid drug for antisense oligonucleotide(ASO), siRNA, shRNA, etc.; 4)Proteolysis targeting chimeras (PROTACs)for targeted protein degradation; 5)Inorganic metal drugs.

Targeting ligand compatible space of polysaccharide-based drug delivery system platform with AI-assisted discovery efforts 

Through computational modeling, structural optimization, and multi-parameter screening, the platform demonstrated compatibility with diverse targeting modalities, including: (1) lipid clusters, enabling membrane affinity and tumor penetration enhancement; (2) sugar unit clusters for lectin- or receptor-mediated targeting; (3) peptides and peptide derivatives with high binding specificity; (4) aptamers for programmable nucleic acid-based recognition; and (5) antibody Fab fragments for selective targeting with reduced molecular size and improved tissue penetration. 

These findings suggest that polysaccharide-based delivery systems may serve as a versatile next-generation platform for precision therapeutics across oncology and other disease areas.